Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: a Danish cohort study

TY - JOUR

T1 - Prognostic impact of tumor MET expression among patients with stage IV gastric cancer

T2 - a Danish cohort study

AU - Erichsen, Rune

AU - Kelsh, Michael A

AU - Oliner, Kelly S

AU - Nielsen, Karsten B

AU - Frøslev, Trine

AU - Lænkholm, Anne-Vibeke

AU - Vyberg, Mogens

AU - Acquavella, John

AU - Sørensen, Henrik Toft

N1 - Copyright © 2016 Elsevier Inc. All rights reserved.

PY - 2016/7

Y1 - 2016/7

N2 - PURPOSE: We aimed to investigate the prevalence and prognostic impact of tumor mesenchymal epithelial transition factor (MET) expression in stage IV gastric cancers in a real-world clinical setting because existing evidence is sparse.METHODS: The study included archived cancer specimens from 103 stage IV gastric cancer patients (2003-2010). We analyzed MET-protein expression by immunohistochemistry (MET-positive if ≥25% of tumor cells showed MET expression). We calculated overall survival using the Kaplan-Meier method and hazard ratios comparing mortality among MET-positive and MET-negative patients using Cox regression adjusted for age, gender, and comorbidity.RESULTS: We found that 62.1% (95% confidence interval, 52.0-71.5) of patients had MET-positive tumors. Median survival was lower among patients with MET-positive tumors (3.5 months) than among patients with MET-negative tumors (9.6 months), corresponding to an adjusted hazard ratio of 2.2 (95% confidence interval, 1.3-3.7).CONCLUSIONS: Tumor MET expression is prevalent and has substantial prognostic impact in stage IV gastric cancer patients.

AB - PURPOSE: We aimed to investigate the prevalence and prognostic impact of tumor mesenchymal epithelial transition factor (MET) expression in stage IV gastric cancers in a real-world clinical setting because existing evidence is sparse.METHODS: The study included archived cancer specimens from 103 stage IV gastric cancer patients (2003-2010). We analyzed MET-protein expression by immunohistochemistry (MET-positive if ≥25% of tumor cells showed MET expression). We calculated overall survival using the Kaplan-Meier method and hazard ratios comparing mortality among MET-positive and MET-negative patients using Cox regression adjusted for age, gender, and comorbidity.RESULTS: We found that 62.1% (95% confidence interval, 52.0-71.5) of patients had MET-positive tumors. Median survival was lower among patients with MET-positive tumors (3.5 months) than among patients with MET-negative tumors (9.6 months), corresponding to an adjusted hazard ratio of 2.2 (95% confidence interval, 1.3-3.7).CONCLUSIONS: Tumor MET expression is prevalent and has substantial prognostic impact in stage IV gastric cancer patients.

KW - Journal Article

U2 - 10.1016/j.annepidem.2016.05.002

DO - 10.1016/j.annepidem.2016.05.002

M3 - Journal article

C2 - 27318530

SN - 1047-2797

VL - 26

SP - 500

EP - 503

JO - Annals of Epidemiology

JF - Annals of Epidemiology

IS - 7

ER -